Founder and CEO of Explora BioLabs
- San Diego, California (Greater San Diego Area)
Richard Lin's Overview
- Founder, President and CEO at Explora BioLabs
- Advisory Board Member at Sanguine Biosciences
- Member of the Board at Wormfree World Institute
- Advisory Board Member at Southern California Biotech Center At Miramar College
- Principle Scientist at Ansata Therapeutics
- Director of Physiology at Genset Corp.
- Group Leader at Corvas International
Richard Lin's Experience
Founder, President and CEO
Privately Held; 11-50 employees; Biotechnology industry
May 2004 – Present (10 years 5 months) San Diego
Recognizing the trend of biotech virtualization and a growing market need for quality preclinical contract research providers, I founded Explora BioLabs in 2004 to help local biotech companies with their critical pharmacology research. Started with 2 employees (founders), in a modest 1500 sq ft of lab space. Over the years, I developed Explora into a well respected preclinical contract research company in San Diego. Explora currently operates a total of 33,000 sq ft of preclinical research labs in three different facilities in San Diego, serving about 20-25 biotech companies.
Member of the Board
Wormfree World Institute
April 2012 – Present (2 years 6 months) Greater San Diego Area
Wormfree World is a non-profit organization dedicated towards eradication of intestinal roundworm parasites and reversing their devastating effects via better treatments designed against the parasites that infect humans, better use of the drugs we currently have, better detection of infected peoples, better nutrition, and a cleaner environment for the 4.5 billion people living in tropical countries that are at-risk.
October 2002 – March 2004 (1 year 6 months) La Jolla
While selling off the assets of Genset, I got to know the folks from Ansata, a brand new small startup biotech in La Jolla. Ansata ended up bringing me on board to run pharmacology research. Despite some unexpected challenges, we took a very novel molecule into a new direction and eventually moved it into clinical trial.
Director of Physiology
October 2001 – August 2002 (11 months) San Diego
A lot of events happened in 2001. Dot com bubble bursted, biotech bubble was in full bloom and 9/11 happened. I was in need of changes. An opportunity presented itself at Genset and I took it. There, I changed my research direction from cancer to diabetes. In a short time, I dived deep into diabetes research, participated in major due diligence meetings with companies including genzyme and pharmacia, and participated in international research review meeting in Paris. Before long, Genset was acquired by Serono. I was one of the last employees who helped selling off all the assets and turned off the lights.
September 1999 – September 2001 (2 years 1 month) San Diego
My job at Corvas was to expand their cancer therapeutics portfolio. Corvas focused on targeting serine proteases in cardiovascular diseases. Since many of these proteases also play important roles in cancer, they wanted someone with cancer expertise to help them explore this area. I started several new cancer and angiogenesis models at Corvas, and ran through several candidates using these models.
Public Company; 201-500 employees; Biotechnology industry
July 1998 – August 1999 (1 year 2 months) La Jolla, CA
Axys operated in San Diego for about a year before it closed the San Diego facility and consolidated all operations in its South San Francisco facility. During that year, we were tasked with coming up with new drug discovery programs. Many brainstorming sessions were conducted with our chemist colleagues from San Francisco. Like most employees, I decided to stay in San Diego to look for opportunity rather than moving to San Francisco with a promised job.
Sequana Therapeutics, Inc.
1996 – 1998 (2 years) La Jolla
Sequana was the first large scale gene-hunting biotech company in San Diego. I joined the company to develop high throughput gene targeting technology in order to do large scale target validation in vivo. The ambitious project was halfway off the ground before Sequana merged with Arris and morphed into Axys.
Educational Institution; 10,001+ employees; Higher Education industry
1993 – 1996 (3 years)
Studied the role of a homeobox gene, pem, on embryonic and extra-embryonic tissue development using a gene targeting approach
Richard Lin's Languages
English(Native or bilingual proficiency)
Mandarin Chinese(Native or bilingual proficiency)
Richard Lin's Skills & Expertise
- Strategic Planning
- Customer Service Management
- Drug Discovery
- Technology Transfer
- In Vivo
- Protein Chemistry
- Drug Development
- Stem Cells
- Pharmaceutical Industry
- Molecular Biology
- Cell Culture
- Cell Biology
- Assay Development
- In Vitro
Richard Lin's Education
Richard Lin's Additional Information
- Groups and Associations:
American Association for Cancer Research, BIOCOM
Contact Richard for:
- new ventures
- expertise requests
- business deals
- getting back in touch